© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#non-nucleoside reverse transcriptase inhibitor

Pifeltro

The HIV Life Cycle

HIV Medications

Sustiva

Edurant

Viramune and Viramune XR

Intelence

Rescriptor

Concerns: Resistant Strains

People contracting HIV are increasingly acquiring strains that are resistant to antiretrovirals (ARVs).

Antiretrovirals: A Success Story

Celebrating 20 years of effective HIV treatment

Milestones in the Era of Effective HIV Treatment

Here’s a timeline of the highlights.

Treatment: 8-Week Dosing

HIV treatment taken only every two months is moving closer to reality.

Treatment: Two-Drug Regimen

ViiV Healthcare is beginning Phase III trials of the integrase inhibitor Tivicay and the non-nucleoside reverse transcriptase inhibitor Eduran...

New HIV Med Doravirine Has Half of Sustiva’s Side Effect Rate

Merck’s next-generation NNRTI doravirine (MK-1439) suppresses HIV as well as Sustiva (efavirenz) and leads to half the rate of side effects.

Merck’s Non-Nuke MK-1439 Shows Antiviral Activity, Is Safe and Well Tolerated

Merck’s investigatory non-nuke MK-1439 proved safe and well tolerated—and it displayed robust antiviral activity in a small early trial.

Non-Nuke Lersivirine Promising in First-Time Treatment Takers

Lersivirine, ViiV Healthcare’s experimental NNRTI, achieves similar rates of viral load suppression compared with Sustiva (efavirenz).
Advertisement